220 related articles for article (PubMed ID: 22918928)
21. [The immunotherapy potential of agonistic anti-CD137 (4-1BB) monoclonal antibodies for malignancies and chronic viral diseases].
Alfaro C; Murillo O; Tirapu I; Azpilicueta A; Huarte E; Arina A; Arribillaga L; Pérez-Gracia JL; Bendandi M; Prieto J; Lasarte JJ; Melero I
An Sist Sanit Navar; 2006; 29(1):77-96. PubMed ID: 16670731
[TBL] [Abstract][Full Text] [Related]
22. Some statistical considerations in the clinical development of cancer immunotherapies.
Huang B
Pharm Stat; 2018 Feb; 17(1):49-60. PubMed ID: 29098766
[TBL] [Abstract][Full Text] [Related]
23. A proposal for a simple and inexpensive therapeutic cancer vaccine.
Fahrer AM
Immunol Cell Biol; 2012 Mar; 90(3):310-3. PubMed ID: 21606943
[TBL] [Abstract][Full Text] [Related]
24. De-Risking Immunotherapy: Report of a Consensus Workshop of the Cancer Immunotherapy Consortium of the Cancer Research Institute.
Mellman I; Hubbard-Lucey VM; Tontonoz MJ; Kalos MD; Chen DS; Allison JP; Drake CG; Levitsky H; Lonberg N; van der Burg SH; Fearon DT; Wherry EJ; Lowy I; Vonderheide RH; Hwu P
Cancer Immunol Res; 2016 Apr; 4(4):279-88. PubMed ID: 27036972
[TBL] [Abstract][Full Text] [Related]
25. Approaches to improve development methods for therapeutic cancer vaccines.
Ogi C; Aruga A
Immunol Lett; 2015 Apr; 164(2):100-8. PubMed ID: 25746315
[TBL] [Abstract][Full Text] [Related]
26. Current and Future Applications of Novel Immunotherapies in Urological Oncology: A Critical Review of the Literature.
Özdemir BC; Siefker-Radtke AO; Campbell MT; Subudhi SK
Eur Urol Focus; 2018 Apr; 4(3):442-454. PubMed ID: 29056275
[TBL] [Abstract][Full Text] [Related]
27. The Role of Neoantigens in Naturally Occurring and Therapeutically Induced Immune Responses to Cancer.
Ward JP; Gubin MM; Schreiber RD
Adv Immunol; 2016; 130():25-74. PubMed ID: 26922999
[TBL] [Abstract][Full Text] [Related]
28. Alternative clinical end points in rectal cancer--are we getting closer?
Glynne-Jones R; Mawdsley S; Pearce T; Buyse M
Ann Oncol; 2006 Aug; 17(8):1239-48. PubMed ID: 16873440
[TBL] [Abstract][Full Text] [Related]
29. Clinical considerations in developing dendritic cell vaccine based immunotherapy protocols in cancer.
Murthy V; Moiyadi A; Sawant R; Sarin R
Curr Mol Med; 2009 Aug; 9(6):725-31. PubMed ID: 19689299
[TBL] [Abstract][Full Text] [Related]
30. Immunotherapy and the role of imaging.
Carter BW; Bhosale PR; Yang WT
Cancer; 2018 Jul; 124(14):2906-2922. PubMed ID: 29671876
[TBL] [Abstract][Full Text] [Related]
31. [Cancer immunotherapy: recent breakthroughs and perspectives].
Tartour E; Sandoval F; Bonnefoy JY; Fridman WH
Med Sci (Paris); 2011 Oct; 27(10):833-41. PubMed ID: 22027420
[TBL] [Abstract][Full Text] [Related]
32. Clinical trials of active cancer immunotherapy.
Nawrocki S; Mackiewicz A
Expert Opin Investig Drugs; 2007 Aug; 16(8):1137-41. PubMed ID: 17685864
[TBL] [Abstract][Full Text] [Related]
33. Carbohydrate vaccines as immunotherapy for cancer.
Slovin SF; Keding SJ; Ragupathi G
Immunol Cell Biol; 2005 Aug; 83(4):418-28. PubMed ID: 16033538
[TBL] [Abstract][Full Text] [Related]
34. Cancer vaccines and immunotherapies: emerging perspectives.
Henderson RA; Mossman S; Nairn N; Cheever MA
Vaccine; 2005 Mar; 23(17-18):2359-62. PubMed ID: 15755628
[TBL] [Abstract][Full Text] [Related]
35. Reconsidering the paradigm of cancer immunotherapy by computationally aided real-time personalization.
Kogan Y; Halevi-Tobias K; Elishmereni M; Vuk-Pavlović S; Agur Z
Cancer Res; 2012 May; 72(9):2218-27. PubMed ID: 22422938
[TBL] [Abstract][Full Text] [Related]
36. Current vaccination strategies for prostate cancer.
Joniau S; Abrahamsson PA; Bellmunt J; Figdor C; Hamdy F; Verhagen P; Vogelzang NJ; Wirth M; Van Poppel H; Osanto S
Eur Urol; 2012 Feb; 61(2):290-306. PubMed ID: 22001436
[TBL] [Abstract][Full Text] [Related]
37. The role of regulatory T lymphocytes in the induced immune response mediated by biological vaccines.
López M; Aguilera R; Pérez C; Mendoza-Naranjo A; Pereda C; Ramirez M; Ferrada C; Aguillón JC; Salazar-Onfray F
Immunobiology; 2006; 211(1-2):127-36. PubMed ID: 16446177
[TBL] [Abstract][Full Text] [Related]
38. Cytomegalovirus and immunotherapy: opportunistic pathogen, novel target for cancer and a promising vaccine vector.
Quinn M; Erkes DA; Snyder CM
Immunotherapy; 2016 Feb; 8(2):211-21. PubMed ID: 26786895
[TBL] [Abstract][Full Text] [Related]
39. [Re-Analysis of Cancer Vaccine Patients with Immune-Related Clinical Response Criteria(irRC)].
Nishida K; Saito T; Urakawa S; Mori M; Kakimi K; Doki Y; Wada H
Gan To Kagaku Ryoho; 2018 Oct; 45(10):1466-1468. PubMed ID: 30382047
[TBL] [Abstract][Full Text] [Related]
40. Immune based therapies in cancer.
Krüger C; Greten TF; Korangy F
Histol Histopathol; 2007 Jun; 22(6):687-96. PubMed ID: 17357098
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
